Tempest Therapeutics (NASDAQ:TPST) Receives Outperform Rating from William Blair

Tempest Therapeutics (NASDAQ:TPST)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a research note issued on Wednesday,RTT News reports.

Separately, HC Wainwright reissued a “buy” rating and set a $47.00 target price on shares of Tempest Therapeutics in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $20.75.

Tempest Therapeutics Trading Down 1.8 %

Tempest Therapeutics stock opened at $1.08 on Wednesday. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12. The firm has a 50-day moving average price of $1.21 and a two-hundred day moving average price of $1.98. The firm has a market capitalization of $27.23 million, a price-to-earnings ratio of -0.67 and a beta of -1.78. Tempest Therapeutics has a 52-week low of $0.86 and a 52-week high of $6.00.

Institutional Trading of Tempest Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TPST. Virtu Financial LLC raised its position in shares of Tempest Therapeutics by 69.2% during the 1st quarter. Virtu Financial LLC now owns 28,574 shares of the company’s stock worth $112,000 after buying an additional 11,689 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Tempest Therapeutics during the 2nd quarter worth about $55,000. Fullcircle Wealth LLC bought a new stake in shares of Tempest Therapeutics during the 3rd quarter worth about $87,000. Finally, Empower Advisory Group LLC bought a new stake in shares of Tempest Therapeutics during the 3rd quarter worth about $49,000. 22.52% of the stock is currently owned by institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.